Lineagen offers FirstStepDx PLUS and NextStepDx PLUS, integrated services combining genetic testing, counseling and developmental screening to aid diagnosis of ASD and other developmental delays. The company plans to continue commercializing FirstStepDx PLUS, expand commercialization of NextStepDx PLUS, and apply its clinical research to a broader range of neurodevelopmental and neurological indications. It also has ongoing scientific programs in multiple sclerosis (MS) and chronic obstructive pulmonary disease (COPD). Led by CEO Michael S. Paul, Ph.D., Lineagen recently completed the second and final tranche of its Series C financing to support those commercialization and research efforts. The company previously raised a first tranche of $3.5M in 2013 and obtained a $4M secured debt facility with Silicon Valley Bank as part of the initial tranche. Lineagen provides physicians and patients an integrated genetic testing, counseling and developmental screening service to aid early diagnostic evaluation of individuals with autism spectrum disorders (ASDs) and other childhood developmental disorders. The company is led by CEO Michael S. Paul, Ph.D., and is based in Salt Lake City, Utah. Its core product combines genetic testing with counseling and developmental screening to support clinicians and families. Financially, Lineagen completed a Series C financing and pursued senior secured debt facilities as part of its funding strategy. The company converted $12.6M in outstanding promissory notes into Series B preferred stock as part of its balance-sheet actions. No operating metrics (revenue/users) were disclosed in the article. Lineagen offers comprehensive genetic testing and support/counseling services designed to enable early evaluation of children at risk for disorders of childhood development, including Autism Spectrum Disorders. Its core product set centers on proprietary clinical testing services and physician- and consumer-directed consultative services. The company plans to expand its commercial franchise and introduce new proprietary clinical tests using proceeds from its current raise. Lineagen maintains collaborative relationships with pediatric research institutes including the University of Utah and The Children’s Hospital of Philadelphia. Founded in 2002 and led by CEO Michael Paul, Ph.D., the company previously completed a Series A to fund discovery and development. Lineagen develops genomic tests and services aimed at screening, evaluation and diagnosis of complex disorders and diseases, including autism spectrum disorders. The company is advancing a lead autism program and planned a commercial service launch for September 2010. Lineagen received an additional $5.0m investment from PrairieGold Venture Partners to support further development and the commercial launch. The Series A financing totaled $10.8m after the new investment; Lineagen previously held a $5.8m first close in December 2007. In conjunction with the financing, Mike Jerstad, a partner at PrairieGold Venture Partners, joined Lineagen’s board of directors. The Series A included support from Sanderling Ventures, vSpring Capital and Mesa Verde Venture Partners. LineaGen is a Salt Lake City biotech developing genetic diagnostics. It seeks genomic markers — presumably the single‑nucleotide polymorphisms (SNPs) — associated with conditions including autism, multiple sclerosis, cancer and lung disease. The company plans to turn identified markers into diagnostic tests. LineaGen leverages detailed databases on Utah’s predominately Mormon population and its genealogical records to discover markers. VentureWire reported that LineaGen raised $6 million in a first round of funding from Sanderling Ventures, vSpring Capital and Mesa Verde Partners. The report noted that LineaGen did not have a Web site listed.

Total raised

$46M

Funding rounds

7

Latest round

Series C

Latest activity

Feb 2015